

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)



(10) International Publication Number
WO 2022/238432 A3

(51) International Patent Classification:

A61K 39/00 (2006.01) A61P 37/08 (2006.01)
A61K 39/35 (2006.01) C07K 14/00 (2006.01)
A61P 37/06 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2022/062688

(22) International Filing Date:

10 May 2022 (10.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PA 2021 70225 10 May 2021 (10.05.2021) DK
PA 2021 70363 08 July 2021 (08.07.2021) DK
20220133 26 January 2022 (26.01.2022) NO

(88) Date of publication of the international search report:

22 December 2022 (22.12.2022)

(71) Applicant: NYKODE THERAPEUTICS ASA [NO/NO];
Gaustadalléen 21, 0349 Oslo (NO).

(72) Inventors: FREDRIKSEN, Agnete Brunsvik; Øvre
Rælingsveg 82B, 2005 Rælingen (NO). BERSAAS,
Audun Trygve Haugen; Nordalveien 81, 0584 Oslo (NO).
GRANUM, Stine; Østmarkveien 24, 0687 Oslo (NO).
MYRSET, Heidi; Vestbybakken 3, 1900 Fetsund (NO).

(74) Agent: HØIBERG P/S; Adelgade 12, 1304 Copenhagen K
(DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: CO-EXPRESSION OF CONSTRUCTS AND IMMUNOINHIBITORY COMPOUNDS

(57) Abstract: The present invention relates to vectors, such as DNA plasmids, comprising multiple nucleic acid sequences engineered to be co-expressed as separate molecules. Such separate molecules include a first polypeptide, wherein the first polypeptide comprises a targeting unit that targets antigen-presenting cells, a multimerization unit, such as dimerization unit, and an antigenic unit comprising one or more T cell epitopes of a self-antigen, an allergen, an alloantigen or a xenoantigen, and one or more immunoinhibitory compounds

WO 2022/238432 A3